الفهرس 
Association of CXCR4 expression and clinical outcome in different subsets of de novo acute myeloid leukemia patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Background: Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by the uncontrolled proliferation of hematopoietic stem cells (HSCs) and progenitors with a reduced capacity to differentiate into mature cells. CXC chemokine receptor (CXCR4) and its ligand stromal derived factor-1 (SDF-1/CXCL12) are important players involved in cross-talk between leukemia cells and the bone marrow (BM) microenvironment Methods: 58 patients were recruited for this study suffering from AML with age range between 18 to 60 years presenting between 2013 and 2017. All patients were subjected to Complete Blood Count (CBC) , BM aspiration ,Immunophenotyping, BM trephine biopsy , Immunohistochemical staining with CXCR4 McAb and Cytogenetics when feasible. Results: CXCR4 was widely expressed (55.2%) among the studied patients. There was significant relation between CXCR4 and patients{u2019} outcome. 15(71.4%) of died patients were CXCR4 positive .The estimated mean time until death among CXCR4 negative cases is 37.6+4.04 months which is longer than that of CXCR4 positive cases who had mean of 20.04+ 4.9 months P=0.016.The risk for death among CXCR4 positive cases was higher than CXCR4 negative cases with hazard ratio= 2.147 with significance relation p= 0.048